Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Laboratoires CTRS

- PMLiVE

AstraZeneca settles with generic rivals in Crestor patent challenge

Blocks competition in US until May 2016

- PMLiVE

CHMP backs oral MS drugs from Sanofi, Biogen Idec

Tecfidera and Aubagio recommended for use in Europe

Sanofi reception

Follow-up data suggests long-term benefit of Sanofi’s Lemtrada in MS

Drug has a durable effect on relapse rates and disability progression

- PMLiVE

Additional 2,300 jobs to go at AstraZeneca

Soriot sets out strategy to return to growth

- PMLiVE

Bayer’s Eylea data not suitable, says IQWiG

German HTA body unhappy with Lucentis comparison data and turns down Bayer-Regeneron wet AMD drug

- PMLiVE

AstraZeneca cuts 1,600 jobs in overhaul of global operations

US and UK affected as Soriot pushes ahead with R&D restructuring

- PMLiVE

Bayer sues Glenmark over its skin disorder generic

India-based firm files for US approval of its version of Finacea

- PMLiVE

FDA knocks back Xarelto once again in ACS

Major setback for Bayer and Johnson & Johnson's oral anticoagulant

- PMLiVE

Bayer fails to overturn Nexavar compulsory licence in India

Natco Pharma allowed to sell cut-price version of cancer drug

- PMLiVE

AZ loses Crestor patent battle in Australia

Follows challenge from Apotex

- PMLiVE

Novo’s Lantus rival Tresiba hits European markets

Company says its insulin degludec is a more flexible alternative to Sanofi's product

- PMLiVE

Bayer pins hopes on five potential blockbusters

Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of €5.5bn by 2015

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links